Tang Qi, Song Yi, Li Xuesong, Meng Maxwell, Zhang Qian, Wang Jin, He Zhisong, Zhou Liqun
Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, National Urological Cancer Center, Beijing 100034, China.
Department of Urology, University of California, San Francisco, CA 94143-0738, USA.
Biomed Res Int. 2015;2015:163423. doi: 10.1155/2015/163423. Epub 2015 Sep 3.
To evaluate the prognostic outcomes and risk factors for renal cell carcinoma (RCC) patients with venous tumor thrombus in China.
We reviewed the clinical information of 169 patients who underwent radical nephrectomy and thrombectomy. Overall and cancer-specific survival rates were analyzed. Univariate and multivariate analyses were used to investigate the potential prognostic factors.
The median survival time was 63 months. The five-year overall survival and cancer-specific survival rate were 53.6% and 54.4% for all patients. For all patients, significant survival difference was only observed between early (below hepatic vein) and advanced (above hepatic vein) tumor thrombus. However, significant differences existed between both RV/IVC and early/advanced tumor thrombus groups in N0M0 patients. Multivariate analysis demonstrated that higher tumor thrombus level (p = 0.016, RR = 1.58), N (p = 0.013, RR = 2.60), and M (p < 0.001, RR = 4.14) stages and adrenal gland invasion (p = 0.001, RR = 4.91) were the most significant negative prognostic predictors.
In this study, we reported most cases of RCC patients with venous extension in China. We proved that patients with RCC and venous tumor thrombus may have relative promising long-term survival rate, especially those with early tumor thrombus.
评估中国肾细胞癌(RCC)合并静脉瘤栓患者的预后结局及危险因素。
回顾性分析169例行根治性肾切除术及瘤栓切除术患者的临床资料。分析总生存率和癌症特异性生存率。采用单因素和多因素分析探讨潜在的预后因素。
中位生存时间为63个月。所有患者的5年总生存率和癌症特异性生存率分别为53.6%和54.4%。对于所有患者,仅在早期(肝静脉以下)和晚期(肝静脉以上)瘤栓患者之间观察到显著的生存差异。然而,在N0M0患者中,RV/IVC组和早期/晚期瘤栓组之间均存在显著差异。多因素分析表明,较高的瘤栓水平(p = 0.016,RR = 1.58)、N分期(p = 0.013,RR = 2.60)、M分期(p < 0.001,RR = 4.14)以及肾上腺侵犯(p = 0.001,RR = 4.91)是最显著的负面预后预测因素。
在本研究中,我们报告了中国大多数RCC合并静脉延伸的病例。我们证明,RCC合并静脉瘤栓的患者可能具有相对较好的长期生存率,尤其是那些瘤栓早期的患者。